Daily Roundup

CUV.ASX MIN.ASX SDR.ASX ALC.ASX TLX.ASX

Clinuvel Pharmaceuticals Secures Year-Round Treatment Approval

Clinuvel Pharmaceuticals has received great news from the European Medicines Agency (EMA). The regulatory body has approved year-round treatment with Clinuvel's drug SCENESSE for adult erythropoietic protoporphyria (EPP) patients. This means the label now removes the recommended maximum annual dose, allowing EPP patients to receive an implant every two months.

The EMA's Committee for Medicinal Products for Human Use (CHMP) reviewed over 15 years of clinical trial data and real-world evidence, determining that there are no significant safety concerns with the ongoing administration of SCENESSE. This is a major win for EPP patients in Europe, who can now access this vital photoprotective treatment without interruption.

Mineral Resources Refinances Debt with $700M Notes Offering

In other news, Mineral Resources Limited has priced a $700 million offering of 7.000% Senior Unsecured Notes due April 2031. The company plans to use the proceeds to refinance its existing $700 million 8.125% Senior Unsecured Notes due May 2027.

The new notes will pay interest semi-annually and be guaranteed by certain wholly-owned Mineral Resources subsidiaries. This refinancing transaction will help the company optimize its debt structure and reduce borrowing costs.

SiteMinder Unveils Smart Platform Innovations

Hotel technology leader SiteMinder is showcasing the latest advancements to its Smart Platform, aimed at helping hoteliers maximize revenues. The centerpiece is the new Dynamic Revenue Plus solution, which leverages real-time data, AI-powered insights, and seamless execution to streamline revenue management.

SiteMinder is also unveiling the Smart Distribution Program, a collaborative effort with key global distribution partners to enhance hotel connectivity and performance. Additionally, the company is highlighting how it is using its vast data assets and AI capabilities to deliver deeper market intelligence and predictive analytics.

These innovations position SiteMinder's Smart Platform as a comprehensive solution to transform revenue management, distribution, and hotel operations, addressing longstanding industry pain points.

Alcidion Expands Contract with NHS Trust

Alcidion Group Limited has announced an expansion of its contract with North Cumbria Integrated Care NHS Foundation Trust (NCIC). The company will now deliver its MediViewer electronic document management system as an integrated component of the Miya Precision Electronic Patient Record (EPR) solution.

This will provide NCIC clinicians with seamless access to scanned and historical patient documents directly within the EPR workflow. The total contract value for this expansion is approximately $6.8 million over 9.4 years, aligning with NCIC's existing 10-year contract for the Miya Precision EPR.

Telix Pharma Achieves Reimbursement Milestone in the U.S.

Telix Pharmaceuticals has announced a significant milestone in its U.S. commercial strategy. The Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for Telix's next-generation PSMA-PET imaging agent, Gozellix.

This designation enables separate reimbursement for Gozellix under the Hospital Outpatient Prospective Payment System, effective October 1, 2025. Patients will also not be subject to the 20% coinsurance under TPT, improving access to this innovative prostate cancer imaging technology.